Literature DB >> 30705114

Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Ilaria Del Giudice1, Robin Foà2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30705114      PMCID： PMC6355490          DOI： 10.3324/haematol.2018.207399

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  27 in total

1.  Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Ulf Thunberg; Karin Karlsson; Fiona Murray; Anna Laurell; Kerstin Willander; Gunilla Enblad; Mats Merup; Juhani Vilpo; Gunnar Juliusson; Christer Sundström; Ola Söderberg; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

2.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

3.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

4.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

5.  Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.

Authors:  Paolo Ghia; Kostas Stamatopoulos; Chrysoula Belessi; Carol Moreno; Stefania Stella; Giuseppe Guida; Ariane Michel; Marta Crespo; Nikolaos Laoutaris; Emili Montserrat; Achilles Anagnostopoulos; Guillaume Dighiero; Athanasios Fassas; Federico Caligaris-Cappio; Frédéric Davi
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

6.  BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.

Authors:  Anna Guarini; Sabina Chiaretti; Simona Tavolaro; Roberta Maggio; Nadia Peragine; Franca Citarella; Maria Rosaria Ricciardi; Simona Santangelo; Marilisa Marinelli; Maria Stefania De Propris; Monica Messina; Francesca Romana Mauro; Ilaria Del Giudice; Robert Foà
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

7.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.

Authors:  Stefano Iacovelli; Eva Hug; Sara Bennardo; Marcus Duehren-von Minden; Stefania Gobessi; Andrea Rinaldi; Mirza Suljagic; Daniel Bilbao; Giulia Bolasco; Julia Eckl-Dorna; Verena Niederberger; Francesco Autore; Simona Sica; Luca Laurenti; Hongsheng Wang; Richard J Cornall; Stephen H Clarke; Carlo M Croce; Francesco Bertoni; Hassan Jumaa; Dimitar G Efremov
Journal:  Blood       Date:  2015-01-06       Impact factor: 22.113

Review 9.  ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Authors:  J Malcikova; E Tausch; D Rossi; L A Sutton; T Soussi; T Zenz; A P Kater; C U Niemann; D Gonzalez; F Davi; M Gonzalez Diaz; C Moreno; G Gaidano; K Stamatopoulos; R Rosenquist; S Stilgenbauer; P Ghia; S Pospisilova
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

10.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations.

Authors:  R Rosenquist; P Ghia; A Hadzidimitriou; L-A Sutton; A Agathangelidis; P Baliakas; N Darzentas; V Giudicelli; M-P Lefranc; A W Langerak; C Belessi; F Davi; K Stamatopoulos
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528
View more
  4 in total

1.  Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).

Authors:  Neda Alrawashdh; Joann Sweasy; Brian Erstad; Ali McBride; Daniel O Persky; Ivo Abraham
Journal:  Ann Hematol       Date:  2021-07-19       Impact factor: 3.673

2.  IGHV1 status in chronic lymphocytic leukemia identify ethnic groups with an aggressive clinical course (Comment to Giudice ID, Foà R. Haematologica. 2019;104(2):219-221).

Authors:  Teresa Amato; Massimo Granai; Lorenzo Leoncini; Cristiana Bellan
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

3.  Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients.

Authors:  Mariam Ibáñez; Esperanza Such; Alessandro Liquori; Gayane Avestisyan; Rafael Andreu; Ana Vicente; María José Macián; Mari Carmen Melendez; Mireya Morote-Faubel; Pedro Asensi; María Pilar Lloret; Isidro Jarque; Isabel Picón; Alejandro Pacios; Eva Donato; Carmen Mas-Ochoa; Carmen Alonso; Carolina Cañigral; Amparo Sempere; Samuel Romero; Marta Santiago; Guillermo F Sanz; Javier de la Rubia; Leonor Senent; Irene Luna
Journal:  Diagnostics (Basel)       Date:  2022-04-11

4.  IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications.

Authors:  Massimo Granai; Teresa Amato; Arianna Di Napoli; Raffaella Santi; Federica Vergoni; Gioia Di Stefano; Virginia Mancini; Sofya Kovalchuk; Emanuele Cencini; Alberto Giulio Carta; Sara Aversa; Marita Ziepert; Gabriele Cevenini; Stefano Lazzi; Lorenzo Leoncini; Cristiana Bellan
Journal:  Virchows Arch       Date:  2019-12-04       Impact factor: 4.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.